Your browser doesn't support javascript.
loading
Host variation in type I interferon signaling genes (MX1), C-C chemokine receptor type 5 gene, and major histocompatibility complex class I alleles in treated HIV+ noncontrollers predict viral reservoir size.
Siegel, David A; Thanh, Cassandra; Wan, Eunice; Hoh, Rebecca; Hobbs, Kristen; Pan, Tony; Gibson, Erica A; Kroetz, Deanna L; Martin, Jeffrey; Hecht, Frederick; Pilcher, Christopher; Martin, Maureen; Carrington, Mary; Pillai, Satish; Busch, Michael P; Stone, Mars; Levy, Claire N; Huang, Meei-Li; Roychoudhury, Pavitra; Hladik, Florian; Jerome, Keith R; Kiem, Hans-Peter; Henrich, Timothy J; Deeks, Steven G; Lee, Sulggi A.
  • Siegel DA; Department of Medicine, Division of HIV, Infectious Diseases & Global Medicine.
  • Thanh C; Department of Medicine, Division of Experimental Medicine.
  • Wan E; Institute of Human Genetics.
  • Hoh R; Department of Medicine, Division of HIV, Infectious Diseases & Global Medicine.
  • Hobbs K; Department of Medicine, Division of Experimental Medicine.
  • Pan T; Department of Medicine, Division of Experimental Medicine.
  • Gibson EA; Department of Medicine, Division of Experimental Medicine.
  • Kroetz DL; Department of Bioengineering and Therapeutic Sciences.
  • Martin J; Department of Biostatistics & Epidemiology, University of California San Francisco, California.
  • Hecht F; Department of Medicine, Division of HIV, Infectious Diseases & Global Medicine.
  • Pilcher C; Department of Medicine, Division of HIV, Infectious Diseases & Global Medicine.
  • Martin M; Basic Science Program, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, and Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
  • Carrington M; Basic Science Program, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, and Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
  • Pillai S; Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts.
  • Busch MP; Vitalant Blood Bank, San Francisco, California.
  • Stone M; Vitalant Blood Bank, San Francisco, California.
  • Levy CN; Vitalant Blood Bank, San Francisco, California.
  • Huang ML; Department of Obstetrics and Gynecology.
  • Roychoudhury P; Department of Laboratory Medicine and Pathology, University of Washington.
  • Hladik F; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • Jerome KR; Department of Laboratory Medicine and Pathology, University of Washington.
  • Kiem HP; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • Henrich TJ; Department of Obstetrics and Gynecology.
  • Deeks SG; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • Lee SA; Department of Laboratory Medicine and Pathology, University of Washington.
AIDS ; 37(3): 477-488, 2023 03 01.
Article en En | MEDLINE | ID: mdl-36695358
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Interferón Tipo I / Infecciones por VIH / VIH-1 Tipo de estudio: Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Interferón Tipo I / Infecciones por VIH / VIH-1 Tipo de estudio: Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article